Defibrase の生体内投与による線溶の出現について

抄録

We have alreadey elucidated the administration of Defibrase as a defibrinating agent promoted fibrinolysis. In this study, we carried out animal experiment using hybrid dogs for investigating the mechanism of fibrinolysis induced by the administration of Defibrase, especially on the relationship between fibrinopeptide A, des A fibrinmonomer and Defibrase itself and a release reaction of plasminogen activator from vascular wall.
Fibrinolytic phenomenon was not observed at all on the intravenous administration of 0.18mg/kg body weight of fibrinopeptide A. However, when 7.5, 17.0 and 34mg/Kg body weight of des A fibrinmonomer were administered, the concentration of FDP was increased and fibrinogen and α₂-plasmin inhibitor levels were decreased depending on the dosage administered. Similar findings were also found following Defibrase administration. To observe a release reaction of plasminogen activator from vascular wall, perinfusion experiments were performed using hybrid dog's hind limbs. Among groups of 20, 50 and 100BU of Defibrase administration in a way of one shot injecton, only three out of five dogs in a group received 100BU of Defibrase showed release of 0.1IU/ml of plasminogen activator, although which would not be strong enough to promote fibrinolysis.
The fact that des A fibrinmonomer, which is a secondary byproduct on the administration of Defibrase, may play a major role in fibrinolysis phenomenon induced by a release of plasminogen activator from vascular wall should be considered in the administration of Defibrase.